| Abstract | OBJECTIVE: To estimate the antitumor efficacy of dolastatin-10 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of dolastatin-10 in these patients. METHODS: Patients received dolastatin-10 400 microg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles. RESULTS: Of 28 patients evaluable for response, there were no complete or partial responses. Seven patients had stable disease and 21 patients had increasing disease. CONCLUSION: Dolastatin-10 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested. |
| Authors | Mark A Hoffman, John A Blessing, Samuel S Lentz, Gynecologic Oncology Group Study
(Affiliation: Division of Hematology-Oncology, Long Island Jewish Medical Center, Campus of the Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA. hoffman at lij.edu)
|
| Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 89
Issue 1
Pg. 95-8
(Apr 2003)
ISSN: 0090-8258 United States |
| PMID | 12694660
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
|
| Chemical References |
- Antineoplastic Agents
- Depsipeptides
- Oligopeptides
- Organoplatinum Compounds
- dolastatin 10
|
| Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Depsipeptides
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Oligopeptides
(adverse effects, therapeutic use)
- Organoplatinum Compounds
(pharmacology)
- Ovarian Neoplasms
(drug therapy)
|
